The protective effect of melatonin on neural stem cell against LPS-induced inflammation by �넚二쇳쁽 & �씠醫낆�
Research Article
The Protective Effect of Melatonin on Neural Stem
Cell against LPS-Induced Inflammation
Juhyun Song,1 So Mang Kang,1,2 Kyoung Min Lee,3 and Jong Eun Lee1,2
1 Department of Anatomy, Yonsei University College of Medicine, Brain Korea 21 Project for Medical Science,
50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea
2 BK21 Plus Project for Medical Sciences and Brain Research Institute, Yonsei University College of Medicine,
Seoul 120-752, Republic of Korea
3 Department of Neurology, Seoul National University College of Medicine, Seoul 151-742, Republic of Korea
Correspondence should be addressed to Jong Eun Lee; jelee@yuhs.ac
Received 10 August 2014; Revised 5 November 2014; Accepted 13 November 2014
Academic Editor: Janusz Blasiak
Copyright © 2015 Juhyun Song et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Stem cell therapy for tissue regeneration has several limitations in the fact that transplanted cells could not survive for a long time.
For solving these limitations, many studies have focused on the antioxidants to increase survival rate of neural stem cells (NSCs).
Melatonin, an antioxidant synthesized in the pineal gland, plays multiple roles in various physiological mechanisms. Melatonin
exerts neuroprotective effects in the central nervous system. To determine the effect of melatonin onNSCs which is in LPS-induced
inflammatory stress state, we first investigated nitric oxide (NO) production and cytotoxicity usingGriess reagent assays, LDHassay,
and neurosphere counting. Also, we investigated the effect of melatonin on NSCs by measuring the mRNA levels of SOX2, TLX,
and FGFR-2. In addition, western blot analyses were performed to examine the activation of PI3K/Akt/Nrf2 signaling in LPS-
treated NSCs. In the present study, we suggested that melatonin inhibits NO production and protects NSCs against LPS-induced
inflammatory stress. In addition, melatonin promoted the expression of SOX2 and activated the PI3K/Akt/Nrf2 signaling under
LPS-induced inflammation condition. Based on our results, we conclude that melatoninmay be an important factor for the survival
and proliferation of NSCs in neuroinflammatory diseases.
1. Introduction
Melatonin is a well-known free radical scavenger, antioxidant
[1, 2], and antiapoptotic agent [3, 4]. Circulating melatonin
is synthesized in the pineal gland as well as in peripheral
tissues and is secreted at high levels in a circadian manner
[5]. Melatonin has a variety of important physiological
functions, including circadian rhythm regulation as well
as visual, reproductive, cerebrovascular, neuroendocrine,
and neuroimmunological actions [6, 7]. Melatonin exerts
neuroprotective effects in many pathological conditions of
the central nervous system (CNS) including Parkinson’s
disease, Alzheimer’s disease, and ischemic brain injury [8,
9]. Recently, it has been reported that melatonin influences
cell growth and differentiation of neural stem cells (NSCs)
[10, 11]. NSCs are characterized as self-renewing, immature,
undifferentiated, and multipotent, indicating that they can
differentiate into neurons, astrocytes, and oligodendrocytes
[12]. Lately, NSCs have been known as the therapeutic target
for neurodegenerative disease. However, several problems
should be solved for NSC’s clinical application [13, 14].
NSC’s survival and proliferation ability are important for
increasing the therapeutic potential of NSCs in injured
tissue [15, 16]. The effects and mechanism of melatonin on
NSC proliferation, apoptosis, and differentiation have been
evaluated. However, its mechanism in neuroinflammation
is currently unclear. Neuroinflammatory responses result
in synaptic impairment, neuronal death, and the exacer-
bation of several disease pathologies within the brain [17,
18]. An excessive inflammatory response results in severe
neurodegenerative diseases [19]. In neuroinflammation state,
damaged neurons can be repaired by NSCs [20]. Therefore,
the survival, self-renewal, proliferation, and differentiation of
NSCs have been emphasized in inflammatory environment
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[21]. Melatonin protects brain injury against LPS-induced
inflammatory condition in vivo [22] and regulates antiox-
idant genes of LPS-stimulated macrophages in vitro [23].
In the present study, we investigated the role of melatonin
in NSCs during LPS-induced inflammation. Nitric oxide
(NO) is an inflammatory molecule [24–26]. NO causes
neuronal apoptosis by inhibiting neuronal respiration, which
increases glutamate release and results in NMDA receptor-
mediated excitotoxic cell death [27]. High NO levels exert
their toxic effects through multiple mechanisms including
lipid peroxidation, mitochondrial damage, protein nitration
and oxidation, depletion of antioxidant reserves, modulation
of various signaling pathways, and DNA damage [25, 28, 29].
NO can also induce apoptosis in a variety of cultured cell
types, including neurons [30–32], and contribute to the death
of neurons in CNS diseases such as ischemic stroke [33] and
Alzheimer’s disease [34]. In addition, NO is involved in the
determination of neural precursor cell (NPC) fate [35] and
NSCproliferation [36].Melatonin suppressesNOproduction
through various mechanisms [37]. Here, we confirmed the
inhibitory effect of melatonin on NO production of NSCs
against LPS-induced inflammatory stress. Melatonin also
influences the proliferation and differentiation activity of
NSCs [10]. The transcription factor SRY- (sex-determining
region-) box 2 (SOX2) is an important functional marker of
NPCs and plays a critical role in self-renewal and neuronal
differentiation [38]. NPCs require SOX2 at an early stage
of differentiation, promoting dorsal root ganglia (DRG)
expression of NGN1 and Mash1 [39, 40]. SOX2 regulates
important functions inNSCs of the CNS as well as in a variety
of other tissue-specific stem/progenitor cells [41]. Orphan
nuclear receptor TLX is an essential transcriptional regulator
ofNSCsmaintenance and self-renewal in the adult brain [42].
Fibroblast growth factor receptor-2 (FGFR-2) promotes self-
renewal of radial glial cells, increasing neuron production
[43, 44], and is associated with the proliferation of embryonic
stem cells [44]. Also, FGFR-2 regulates neurogenesis and the
number of proliferative cells [45]. Therefore, we investigated
whether or not melatonin influences SOX2, TLX, and FGFR-
2 expression as crucial factors of NSC proliferation, self-
renewal, and survival. Nuclear factor-erythroid 2-related
factor 2 (Nrf2) controls the expression of diverse protective
genes in response to oxidative stress [46]. Nrf2 induces a
cellular rescue pathway that protects against LPS-induced
inflammatory stress [47].Nrf2 enhances cytoprotection in the
presence of active phosphatidylinositol 3-kinase (PI3K)/Akt
signaling [48]. Melatonin increases the mRNA and protein
levels of antioxidant enzymes via Nrf2 activation [49, 50]. In
the present study, we examined whether melatonin regulates
Nrf2 activation in LPS-treated NSCs. Our results suggest
the possibility of melatonin as a regulator of NSC’s survival
and proliferation for the treatment of neuroinflammatory
response.
2. Materials and Methods
2.1. Experimental Animals. Pregnant imprinting control
region (ICR) (E14) mice were obtained from Coatech in
Seoul, Republic of Korea. Mice were housed under constant
light, temperature, and humidity conditions. All animal
procedures were performed according to a protocol approved
by the Yonsei University Animal Care andUse Committee, in
accordance with NIH guidelines.
2.2. Cortical NSC Culture. Embryos (E14) were extracted
from placental tissue. Cortices were aseptically dissected
from the brains of fetuses and placed in Hank’s balanced salt
solution (HBSS) (Gibco, NY,USA). Tissues were triturated by
repeated passage through a fire-polished constricted Pasteur
pipette. The dispersed tissues were allowed to settle for
3min. Supernatants were transferred to a fresh tube and
centrifuged at 1,000 g for 5min. Pellets were resuspended
in NSC basal media with a proliferation supplement (Stem
Cell Technologies, CA, USA), 20 ng/mL epidermal growth
factor (EGF, Invitrogen, CA, USA). Cells excluding trypan
blue were counted. Cells were plated in a T 75 flask at a
density of 2.5 × 104 cells/mL. Cultures were maintained in
a humidified atmosphere of 95% air and 5% CO
2
at 37∘C.
After 3 days of culture, the cells proliferated and formed
primary neurospheres. The primary neurospheres composed
of NSCs were harvested by centrifugation, dissociated using
Accumax (Sigma, MO, USA) into single cells.The single cells
were seeded in culture plates precoated with 0.001% poly L-
ornithine (Sigma, MO, USA).The single cells were incubated
for 5 days to form a sufficient number of neurospheres.
Culture media was replaced every 3 days. NSCs of 2-3
passages were used for experiments [10].
2.3. Experimental Procedure. Melatonin was purchased from
Sigma (Sigma, MO, USA) and dissolved in ethanol. An
equivalent volume of ethanol (final: 0.01%) or distilled water
was added to control wells and all melatonin-containing
wells. The effects of melatonin on the proliferative activity
of the NSCs were evaluated by counting the number of
neurospheres and measuring the size of neurospheres. The
single cell suspensions from primary neurospheres were
prepared by a centrifugation (300 g, 3min) followed by
a mechanical dissociation. After incubating for 3 days,
the NSCs were treated with melatonin and subsequently
were cultured for 2-3 days. We used 100 nM melatonin for
subsequent experiments. Also, the NSCs were exposed to
100 ng/mL or 1 𝜇g/mL LPS (Sigma, MO, USA) to study LPS-
induced cytotoxic injury. After incubating for 3 days from
primary neurosphere reseeding, the NSCs were pretreated
with melatonin, and then after 1 day the NSCs were exposed
to 100 ng/mL or 1 𝜇g/mL LPS. In the control group, cells
were not exposed to LPS and melatonin. Also, NSCs were
pretreated with wortmannin (a PI3K inhibitor) (Sigma, MO,
USA) at 3 hr before melatonin treatment. At least three
different experiments were performed using separate cell
preparations, and triplicate determinations were performed
for each experiment.
2.4. Measurement of Lactate Dehydrogenase (LDH) Activity.
The release of LDH is a widely used index of cellular injury
[51]. LPS-induced cytotoxicity was quantified by measuring
the amount of LDH released into the culture media from
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injured cells [52, 53]. LDH release (cytotoxicity %) was
calculated by dividing the value at the experimental time
point by the maximum value. The maximum LDH release
was measured after freezing each culture at −70∘C overnight,
followed by rapid thawing, which induced nearly complete
cell damage.
2.5. Measurement of Nitrite Production. Nitrite production
was determined in the supernatants of cultured cells.The cells
were seeded in 96-well plate at density of 5 × 104 cells/well.
Cells were incubated overnight. Thereafter media was dis-
carded and cells were exposed to treatments as described
earlier. After treatmentsmedia fromeachwell was transferred
to fresh tube. After centrifugation, 100 𝜇L of the supernatant
was transferred to fresh 96-well plate, mixed with an equal
volume of Griess reagent. The plate was incubated in the
dark for 15min at room temperature. The absorbance of the
reaction product was measured at 540 nm using a microplate
reader (Bio-Rad, CA, USA). Nitrite concentration in control
and treated cells was calculated using sodium nitrite standard
reference curve and expressed as 𝜇M nitrite/mL [54].
2.6. Measurement of Neurosphere Size. Images of the neuro-
spheres cultures were taken using an inverted microscope
(Olympus, Tokyo, Japan). The magnification of the image
(×10) covered a significant area of each well from 24-well
plates. An image analysis program (Image J) was used
to analyze the size of neurospheres. Ten nonoverlapping
fields were randomly selected from each well, and images
were captured using a fluorescence microscopy (Olympus,
Tokyo, Japan). Randomly chosen fields were counted. All
experiments were carried out 3 times [55].
2.7. Neurosphere Counting. The single cell suspension of
EGF-expanded NSCs was seeded in nontreatment 96-well
plate (Sigma, MO, USA) at a cell density of 5 × 104 cells/well
andwas incubated for 5 days. After treatingmelatonin and/or
LPS, the fixed area (10mm2) at the center of each well was
converted into a digital image using a digital still camera
(Olympus, Tokyo, Japan) and the number of neurospheres
whose diameter was over 60 𝜇Mwas counted by Image J.
2.8. WST-8 Assay. The indirect counting of viable cells was
carried out by WST-8 assay using a Cell Counting −8 kit
(Sigma, MO, USA). The dissociated NSCs from the primary
neurosphere were reexpanded with EGF in nontreatment 96-
well plate (Sigma, MO, USA) at a cell density of 5 × 104
cells/well. After 5-day incubation periods in the melatonin
and/or LPS, 10 𝜇L of the Cell Counting −8 kit (Sigma, MO,
USA) solution was added to each well and incubated for
an additional 4 hr at 37∘C. The absorbance at 450 nm was
measured by the microplate reader (Bio-Rad, CA, USA) and
the net absorbance subtracting the value of cell-free wells was
calculated.
2.9. Hoechst-Propidium Iodide Staining. Cell viability was
evaluated by staining NSCs with Hoechst 33258 dye (Sigma,
MO, USA) and propidium iodide (PI; Sigma, MO, USA).
Hoechst dye was added to the culture media (2-3𝜇g/mL) and
samples were maintained at 37∘C for 30min. PI solution was
added (2–5 𝜇g/mL) just before observation using anOlympus
microscope equipped with epifluorescence and a UV filter
block. PI-positive cells were counted as dead cells.
2.10. Western Blot Analysis. Equal amounts of protein
(50 𝜇g) were extracted from NSC cultures. They were elec-
trophoresed on 10%–12% SDS-polyacrylamide gels. Sepa-
rated proteins were electrotransferred to Immunobilon-NC
membranes (Millipore,MA, USA).Membranes were blocked
for 1 hr at room temperature with 5% skim milk in Tris-
buffered saline and 0.1% Tween-20 (TBST). The primary
antibodies used were PI3K (1 : 2000, Millipore, MA, USA),
Akt (1 : 2000, Millipore, MA, USA), Nrf2 (1 : 2000, Millipore,
MA, USA), and 𝛽-actin (1 : 1000, Santa Cruz, CA, USA).
Blots were incubated with the primary antibodies overnight
at 4∘C. Membranes were washed three times (5min each)
with TBST. The secondary antibodies were anti-rabbit and
anti-mouse (1 : 3000, New England Biolabs, MA, USA) and
were incubated for 1 hr at room temperature. After washing
with TBST (0.05% Tween-20) three times, immunoreactive
signals were detected using chemiluminescence and an ECL
detection system (Amersham Life Science, UK) with the LAS
4000 program.
2.11. Reverse Transcription-PCR (RT-PCR). To confirm
SOX2, TLX, and FGFR-2 expression in melatonin treated
NSCs and control NSCs, reverse transcription- (RT-) PCR
was performed using SOX2-specific primers and TLX-
specific primers. Briefly, samples were lysed with Trizol
reagent (Invitrogen, CA, USA) and total RNA was extracted
according to the manufacturer’s protocol. cDNA synthesis
from mRNA and sample normalization were performed
using RT-PCR. PCR was performed using the following
thermal profile, 10min at 95∘C; 40 cycles of denaturing at
95∘C for 15 seconds, annealing for 30 seconds at 60∘C, and
elongation at 72∘C for 30 seconds; final extension for 10min
at 72∘C, and paused at 4∘C. PCR was carried out using the
following primers: TLX F: GCTTTCTTCACAGCGGTCAC,
R: GCAGACACAGCGGTCAACT; SOX2 F: CCCCCG-
GCGGCAATAGCA, R: TCGGCGCCGGGG AGATACAT;
FGFR-2 F: ATA AGG TAC GAA ACC AGC ACT G, R:
GGT TGA TGG ACC CGT ATT CAT TC; GAPDH F:
GGCATGGACTGTGGTCATGAG, R: TGCACCACC-
AACTGCTTAGC. PCR products were electrophoresed in
1.5% agarose gels stained with ethidium bromide.
2.12. Immunocytochemistry. To confirm the stemness of
NSCs, NSCs were plated on coverslips (5 × 104 cells/well)
coated with poly-D-lysine. After incubation, the medium
was removed and NSCs were washed three times with
phosphate-buffered saline (PBS) for immunostaining. NSCs
were fixed in 4% paraformaldehyde in PBS for 30min at
room temperature and rinsed with PBS three times for
5min and permeabilized with 0.1% Triton X-100 for 30min
at room temperature. NSCs were incubated with primary
antibody overnight at 4∘C. The following primary antibody
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Figure 1: The measurement of cell cytotoxicity and nitrite production in LPS-induced inflammation. (a) Cytotoxicity (%) was measured
using lactate dehydrogenase (LDH) assays. The cytotoxicity (%) was approximately 65% in the LPS (100 ng/mL) treatment group and 80%
in the LPS (1 𝜇g/mL) treatment group. Upon the addition of melatonin (100 nM), the cytotoxicity (%) in all LPS treatment groups decreased
20% compared to the LPS only treatment groups. (b) Nitrite production was measured using Griess reagent assays. Nitrite concentration
was approximately 13 𝜇M in the LPS (100 ng/mL) treatment group and 18 𝜇M in the LPS (1 𝜇g/mL) treatment group. Upon the addition of
100 nMmelatonin, nitrite production was reduced by nearly half in all LPS treatment groups. Non: normal control, Mel (100 nM): melatonin
(100 nM) treated group, LPS (100 ng/mL): LPS (100 ng/mL) treated group, LPS (1𝜇g/mL): LPS (1 𝜇g/mL) treated group, LPS (100 ng/mL) +
Mel (100 nM): melatonin (100 nM) plus LPS (100 ng/mL) treated group, and LPS (100 ng/mL) + Mel (1 𝜇g/mL): melatonin (100 nM) plus LPS
(1 𝜇g/mL) treated group. Data were expressed as mean ± S.E.M and were analyzed statistically using one-way analysis of variance (ANOVA),
followed by Bonferroni’s post hoc. Each experiment included 5 repeats per condition. Differences were considered significant at ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01 (compared to the control group).
was used: anti-mouse SOX2 (1 : 200, Millipore, MA, USA).
After incubating the NSCs with the primary antibodies,
the plates were washed three times with PBS for 5min
and were incubated with goat anti-mouse FITC-conjugated
secondary antibody. NSCs were then counterstained with
4,6-diamidino-2-phenylindole (DAPI; Sigma, MO, USA) for
10min at room temperature. Immunostained NSCs were
visualized using a Carl-Zeiss confocal microscope LSM 700
(Carl-Zeiss, Jena, Germany).
2.13. Statistical Analysis. Statistical analyses were carried out
using SPSS 18.0 software (IBM Portsmouth, IBM North
Harbour, Portsmouth, Hampshire, UK). Data are expressed
as themean± S.E.M of 3 independent experiments. Statistical
significance in intergroup differenceswas determined by one-
way analysis of variance (ANOVA), followed by Bonferroni’s
post hocmultiple comparison test. Each experiment included
3–5 repeats per condition. Differences were considered sig-
nificant at ∗𝑃 < 0.05, ∗∗𝑃 < 0.01.
3. Results
3.1. Melatonin Protects NSCs against LPS-Induced Inflamma-
tion. To check the protective effects of melatonin on NSCs
in neuroinflammatory diseases, we treated LPS into NSC
cultured media. Under LPS-induced inflammatory stress,
melatonin attenuated apoptosis of NSC. First, to determine
cytotoxicity, we conducted lactate dehydrogenase (LDH)
assays. Cytotoxicity levels were approximately 65% in the LPS
(100 ng/mL) treatment group and 80% in the LPS (1 𝜇g/mL)
treatment group. In the melatonin (100 nM) treatment, the
LPS (100 ng/mL) treatment group is decreased 20%compared
to the LPS (100 ng/mL) treatment group. The LPS (1 𝜇g/mL)
treatment group is decreased 35% compared to the LPS
(1 𝜇g/mL) treatment group. Melatonin (100 nM) treatment
attenuates cytotoxicity in LPS-induced inflammation (Fig-
ure 1(a)). Figure 1(b) shows the nitrite concentration in all
groups using Griess reagent assays. The nitrite concentration
is approximately 13 𝜇M in the LPS (100 ng/mL) treatment
group and 18 𝜇M in LPS (1 𝜇g/mL) treatment group. In the
presence of 100 nM melatonin, LPS (100 ng/mL) attenuated
NO production compared to the LPS only (100 ng/mL)
treatment group.TheLPS (1 𝜇g/mL)withmelatonin (100 nM)
treatment group decreased the nitrite concentration almost
in half compared with the LPS (1 𝜇g/mL) only treatment
group. In the present study, we found that melatonin inhibits
NO production in LPS-treated NSCs. Melatonin may pro-
tect NSCs against LPS-induced inflammation by reducing
NO. In addition, to confirm the effect of melatonin on
NSC apoptosis against LPS-induced inflammatory stress, we
performed Hoechst 33342 (Hoechst)/propidium iodide (PI)
staining (Figure 2(a)). We investigate only the melatonin
(100 nM) treatment group because Figure 1(a) shows more
clear the protective effect of melatonin in the melatonin
100 nM treatment group than the melatonin 10 nM treatment
group. PI-positive cells (red color) indicate apoptotic NSCs
and Hoechst-positive cells (blue color) indicate live NSCs.
PI-positive cells were increased in the LPS (100 ng/mL)
treatment group compared to the normal control group. The
melatonin (100 nM) group had fewer PI-positive cells than
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Figure 2: The measurement of apoptotic cells after melatonin treatment in LPS-induced inflammation. (a) Apoptotic and live cells were
measured using Hoechst/PI staining. PI-positive cells (red) indicate apoptotic cells and Hoechst-positive cells (blue) indicate live cells. The
LPS (100 ng/mL) treatment group had increased numbers of PI-positive cells compared to the normal control group.Themelatonin (100 nM)
treatment group showed decreased numbers of PI-positive cells compared to the LPS treatment group. The LPS (100 ng/mL) plus melatonin
(100 nM) group had fewer PI-positive cells compared to the LPS only treatment group. Scale bar: 200𝜇m, blue: Hoechst 33342 (Hoechst), and
red: propidium iodide (PI). (b) The number of viable cells was evaluated using WST-8 assay. The melatonin treatment increased the number
of viable cells compared to the normal control group and also protected the cell death under LPS-induced inflammation condition. Data
were expressed as mean ± S.E.M, and each experiment included 4 repeats per condition. Differences were considered significant at ∗𝑃 < 0.05
(compared to the control group).
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Figure 3: The measurement of neurosphere size in LPS-induced inflammation. (a) Neurosphere was observed using bright field microscopy
and neurosphere size was measured using Image J software. Neurosphere sizes were maintained in the melatonin treatment group compared
to the control group. In LPS-induced inflammation, melatoninmaintained neurosphere size compared to the LPS (100 ng/mL) only treatment
group. (b) The graph indicated the percentages of neurosphere size in all groups. The percentage of neurospheres greater than 300𝜇m
was higher in the melatonin treatment group compared to the normal control group. In LPS-induced inflammation, the percentage of
neurospheres greater than 200𝜇m was higher in the melatonin group compared with the LPS only treatment group. Scale bar: 200 𝜇m.
(c) The number of neurospheres whose diameter was over 60 𝜇M was counted by Image J software program. The number of neurospheres
was reduced under LPS-induced inflammation and was increased by melatonin treatment in spite of inflammatory condition. Data were
expressed as mean ± S.E.M, and each experiment included 3 repeats per condition. Differences were considered significant at ∗∗𝑃 < 0.01
(compared to the control group).
the LPS (100 ng/mL) treatment group. In the presence of
melatonin (100 nM), the LPS (100 ng/mL) treatment group
had fewer PI-positive cells compared to the LPS (100 ng/mL)
only treatment group (Figure 2(a)). In addition, wemeasured
the number of viable cells using WST-8 assay (Figure 2(b)).
We confirmed that the number of viable cells was reduced
under LPS-induced inflammatory condition. However, mela-
tonin increased the number of viable cells of LPS-stimulated
NSCs (Figure 2(b)). Figure 2 suggests that melatonin inhibits
the apoptosis of NSCs in LPS-induced inflammation. Taken
together, these results show that melatonin protects NSCs in
LPS-induced inflammation.
3.2. Melatonin Maintains Neurosphere Size in LPS-Treated
NSCs. We confirmed that neurosphere size was maintained
by melatonin treatment in LPS-induced inflammatory con-
ditions. Neurosphere size was measured by using bright field
microscopy (Figure 3(a)). Neurosphere sizesweremaintained
in the melatonin (100 nM) treatment group compared to
the normal control group. Additionally, melatonin (100 nM)
treatment group maintains neurosphere size in LPS-induced
inflammation compared to the LPS (100 ng/mL) only treat-
ment group (Figure 3(a)). Figure 3(b) shows that LPS
(100 ng/mL) treatment decreased neurosphere size compared
to the normal control group. Neurospheres greater than
200𝜇m are fewer in the LPS (100 ng/mL) treatment group
than in the normal control group. In the LPS (100 ng/mL)
with melatonin (100 nM) treatment group, there are more
neurospheres greater than 200𝜇m compared to the LPS
(100 ng/mL) only treatment group. In addition, we counted
BioMed Research International 7
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Figure 4: Immunofluorescent staining to check SOX2 expression. LPS-stimulated NSCs show decreased expression of SOX2 compared to
the normal control NSCs. Melatonin promotes the SOX2 expression of NSCs and also melatonin slightly increases the SOX2 expression in
LPS-stimulated NSCs. 4󸀠,6-Diamidino-2-phenylindole (DAPI): blue, SOX2: green, and scale bar: 200𝜇m.
the number of neurospheres (Figure 3(c)). In LPS-induced
inflammatory condition, the number of neurospheres was
reduced compared to the normal control group. Melatonin
inhibited the decrease of neurospheres in LPS-induced
inflammatory condition (Figure 3(c)). Figure 3 indicates that
melatoninmaintains neurosphere size in normal condition as
well as in LPS-induced inflammation.
3.3. Melatonin Influences the Expression of SOX2, TLX, and
FGFR-2 in LPS-Treated NSCs. To examine the expression of
SOX2, we conducted immunochemical staining using SOX2
antibody in all groups (Figure 4). In the present study, we
confirmed that SOX2-positive NSCs were increased by mela-
tonin not only in normal condition but also in LPS-induced
inflammatory condition (Figure 4). To measure the mRNA
levels of SOX2, TLX, and FGFR-2 as markers of NSC survival
and proliferation, we evaluated SOX2, TLX, and FGFR-
2 using reverse transcription-PCR (RT-PCR) in all groups
(Figure 5). The SOX2 mRNA level decreased in the LPS
(100 ng/mL) treatment group compared to the normal control
group. It increased largely by melatonin in normal condition.
Also, it increased in the melatonin (100 nM) group and LPS
(100 ng/mL) plus melatonin (100 nM) group compared to the
LPS (100 ng/mL) treatment group (Figure 5(a)). The mRNA
level of TLX decreased in the LPS (100 ng/mL) group com-
pared to the normal control group. It slightly increased in the
melatonin (100 nM) treatment group compared with the LPS
(100 ng/mL) treatment group. It also slightly increased in the
LPS (100 ng/mL) plusmelatonin (100 nM) group compared to
the LPS (100 ng/mL) treatment group (Figure 5(b)). However,
we could not assure that melatonin could influence the
LPS-stimulated NSCs because LX mRNA level in melatonin
treatment group showed significant increase of TLX mRNA
level in spite of the LPS-induced inflammation compared
to the LPS treatment group. The mRNA level of FGFR-2
decreased in the LPS (100 ng/mL) treatment group compared
to the normal control group. Also, it increased by melatonin
under LPS-induced inflammatory condition compared to
the only LPS treatment group (Figure 5(c)). The pattern of
FGFR-2 mRNA level shows that melatonin may promote the
expression of FGFR-2 mRNA in LPS-induced inflammatory
condition. Figure 5 indicates that melatonin (100 nM) may
enhance the mRNA expression of SOX2 and FGFR-2 both in
normal condition and in LPS-induced inflammation. In the
present study, our results support that melatonin may affect
SOX2, TLX, and FGFR-2 expression in LPS-treatedNSCs and
suggest thatmelatonin could regulate NSC’s proliferation and
survival in neuroinflammatory disease.
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Figure 5: SOX2 and TLX mRNA expression after melatonin treatment in LPS-induced inflammation. (a) SOX2, (b) TLX, and (c) FGFR-2
mRNA levels weremeasured by using RT-PCR.The LPS (100 ng/mL) treatment group showed lowermRNA levels of SOX2, TLX, and FGFR-2
compared to the normal control group. Melatonin (100 nM) treatment resulted in higher SOX2 and FGFR-2 mRNA levels compared to the
LPS (100 ng/mL) treatment group. In the LPS (100 ng/mL) plus melatonin (100 nM) treatment group, SOX2, TLX, and FGFR-2 mRNA levels
were higher compared to the LPS (100 ng/mL) only treatment group. Data were expressed as mean ± S.E.M, and each experiment included 3
repeats per condition. Differences were considered significant at ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 (compared to the control group).
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Figure 6: The measurement of PI3K/Akt/Nrf2 signaling after melatonin treatment in LPS-induced inflammation. (a) Western blotting
experiments showed that the relative protein expression of PI3K decreased in the LPS (100 ng/mL) treatment group compared to the normal
control group. The relative level of PI3K was elevated in the LPS (100 ng/mL) plus melatonin (100 nM) treatment group compared to the
LPS only treatment group. (b)Western blot analyses showed that the relative protein level of Akt decreased in the LPS (100 ng/mL) treatment
group compared to the normal control group.The relative level of Akt was elevated in the LPS (100 ng/mL) plusmelatonin (100 nM) treatment
group compared to the LPS only treatment group. (c) Western blot analyses showed that the relative protein level of Nrf2 decreased in the
LPS (100 ng/mL) treatment group compared to the normal control group. The relative level of Nrf2 was elevated in the LPS (100 ng/mL) plus
melatonin (100 nM) treatment group compared to the LPS only treatment group. (d) Western blot analyses showed that the relative protein
level of Nrf2 decreased in the melatonin (100 nM) treatment group compared to LPS (100 ng/mL) treatment group. Also, the relative level
of Nrf2 was also attenuated in the LPS (100 ng/mL) plus melatonin (100 nM) treatment group. In all groups, NSCs were treated with 100 nM
wortmannin (a PI3K inhibitor) at 3 hr before melatonin or/and LPS treatment. 𝛽-Actin was used as an internal control. Data were expressed
as mean ± S.E.M, and each experiment included 4 repeats per condition. Differences were considered significant at ∗𝑃 < 0.05, ∗∗𝑃 < 0.01
(compared to the control group).
3.4. Melatonin Activates the PI3K/Akt/Nrf2 Signaling in LPS-
Treated NSCs. To measure the protein expression of PI3K,
Akt, andNrf2, we performedwestern blot analyses (Figure 6).
Figure 6(a) shows that the expression of PI3K decreased
during LPS-induced inflammation. However, expression of
PI3K increased in the melatonin (100 nM) group and the
LPS (100 ng/mL) plus melatonin (100 nM) treatment group.
Figure 6(b) shows that Akt expression decreased during
LPS-induced inflammation. Akt expression increased in the
melatonin (100 nM) group and the LPS (100 ng/mL) plus
melatonin (100 nM) treatment group. Figure 6(c) shows that
Nrf2 expression decreased in LPS-induced inflammation.
However, the expression of Nrf2 increased in the melatonin
(100 nM) group and the LPS (100 ng/mL) plus melatonin
(100 nM) treatment group. To determine the upstream signal-
ing pathways responsible for upregulation of Nrf2 expression,
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we examined the effect of melatonin on the phosphory-
lation of Akt. Wortmannin (a PI3K inhibitor) suppressed
melatonin-induced activation of Akt (Figure 6(d)).We exam-
ined the effects ofwortmannin onNrf2 expression.These data
suggest that PI3K and Akt are involved inmelatonin-induced
upregulation of Nrf2 in NSCs. Taken together, we suggest
that melatonin may promote activation of PI3K/Akt/Nrf2
signaling and also may influence the survival of NSCs under
LPS-induced inflammation.
4. Discussion
Melatonin is a potent free radical scavenger capable of
preventing oxidative stress in a number of biological sys-
tems [56–58]. Melatonin has important actions in oxidative
defense by stimulating antioxidative enzymes [59]. NSC
has the pluripotential ability and so has been known as
a therapeutic target to improve the recovery of injured
tissue in neuroinflammatory disease [60]. NSC’s survival is
important to enhance the therapeutic effect at injury site
[61]. In the present study, we investigated the protective
effect of melatonin in LPS-treated NSCs in vitro. NO can
induce apoptosis in various cells, including neurons [31, 32],
and contributes to the death of neurons in CNS disorders
[33, 34]. Also, NO is related to NPC survival and cell fate
determination of NPCs [35]. Tanaka et al. demonstrated the
role of NO in neural proliferation [36]. NO regulates both
termination of proliferation and initiation of differentiation
of NSCs in the developing cortex [62]. In isolated NSCs
from the subventricular zone (SVZ), high NO concentrations
inhibit NSC proliferation and promote differentiation of
precursors into astrocytes [63, 64]. Vilar et al. demonstrated
that melatonin suppresses NO production in glial cultures
by proinflammatory cytokines through p38MAPK inhibition
[37]. In the present study, our data shows the relationship
betweenmelatonin andNO inLPS-treatedNSCs. In addition,
several studies demonstrated that melatonin is linked with
NSC proliferation and the neurosphere formation [10, 65]. In
the present study, we confirmed that melatonin is associated
with neurosphere formation and maintains the neurosphere
during LPS-induced inflammation. In the CNS, SOX2 as a
member of the Sox family of transcription factors is expressed
inNSCs fromneurogenic regions and regulates stem cell pro-
liferation and differentiation [66]. SOX2 maintains the NSC
state by controlling proliferation and differentiation [66–
68]. Additionally, SOX2 promotes self-renewal potential and
inhibits apoptosis and differentiation [41, 69, 70].The orphan
nuclear receptor TLX is an essential regulator of NSC self-
renewal. TLX maintains adult NSCs in an undifferentiated
and self-renewable state [42]. In adult brain, TLX-positive
cells in the hippocampal dentate gyrus play an important
role in learning and memory [71]. TLX regulates adult
NSC self-renewal [42] through transcriptional repression of
downstream target genes by binding with histone-modifying
enzymes [72–74] or by activating theWnt/𝛽-catenin pathway
[75]. FGF-2 is associated with proliferating NSCs in vivo
and regulating NSCs self-renewal in vitro [76–79]. In the
present study, our data suggests that melatonin influences the
expression of SOX2, TLX, and FGFR-2 in LPS-treated NSCs.
Nrf2 is a transcriptional activator of cytoprotective genes. It
activates transcription in response to ROS [80, 81]. Under
oxidative stress, Nrf2 translocates to the nucleus where it
binds DNA promoters and initiates transcription of antiox-
idative genes and their proteins [82, 83]. Nrf2 activates a
cellular rescue pathway that protects against the LPS-induced
inflammatory response [47]. Nrf2 enhances cytoprotection
by activating PI3K-Akt signaling [84, 85]. Several studies
demonstrated that pharmacological inhibition of the PI3K-
Akt pathway represses nuclear translocation of Nrf2 [86, 87].
Negi et al. [88] reported that melatonin ameliorates neu-
roinflammation and oxidative stress via Nrf2 activation. Nrf2
upregulation bymelatonin resulted in increased expression of
the antioxidant enzyme heme oxygenase-1 (HO-1) [88]. HO-1
is the rate-limiting enzyme that catalyzes heme to biliverdin,
carbon monoxide (CO), and free iron. The byproducts of
HO-1 catabolism have been shown to exhibit protective
effects against oxidative and inflammatory stimuli [89]. HO-1
expression also is related to PI3K/Akt pathway activation [85,
90, 91] to protect cells from oxidative damage and cerebral
ischemia in vitro and in vivo [92, 93]. Several studies demon-
strated thatmelatonin increases themRNA and protein levels
of antioxidant enzymes via Nrf2 activation [49, 50]. In the
present study, we confirmed that melatonin is related to Nrf2
activation in LPS-treated NSCs. Our consequences indicate
that melatonin may promote antioxidant gene expression
by regulating Nrf2 activation to protect NSCs under LPS-
induced inflammation. In addition, considering that NSCs
regulate the survival and neurogenesis by PI3K/Akt signaling
[94], our results indicate that melatonin may promote NSC
survival by regulating Nrf2 activation under LPS-induced
inflammation. To conclude, this study suggests five points:
(1) melatonin inhibits NO production in LPS-treated NSC,
(2) melatonin attenuates the apoptosis of NSC in LPS-
induced inflammation, (3) melatonin affects the neurosphere
formation of NSC against LPS-induced inflammation, (4)
melatonin may regulate SOX2 and FGFR-2 expression in
LPS-treated NSC, and (5) melatonin may induce the acti-
vation of Nrf2 through PI3K/Akt signaling pathway in LPS-
treatedNSC.Hence, we suggest thatmelatoninmay influence
the survival of NSCs in neuroinflammatory diseases.
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